Kar-Lok Wong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kar-Lok Wong has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Dah-Yuu Lu
Department of Pharmacology, School of Medicine, China Medical University, Taichung, Taiwan; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan; Office of Research and Development, Asia University, Taichung, Taiwan
2 shared publications Ssu‐Ming Huang
Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan
2 shared publications- Yuk-Man Leung
Department of Physiology, China Medical University, Taichung, Taiwan
2 shared publications Chi-Wai Cheung
Laboratory and Clinical Research Institute for Pain, Department of Anaesthesiology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China
1 shared publicationChia-Chia Chao
China Med Univ, Grad Inst Neural & Cognit Sci, Taichung 40402, Taiwan
1 shared publicationChia-Huei Lin
China Med Univ, Grad Inst Neural & Cognit Sci, Taichung 40402, Taiwan
1 shared publication
Latest Publications
- 13 December 2018
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 392 (4) , 427-436
Enhancing tetrandrine cytotoxicity in human lung carcinoma A549 cells by suppressing mitochondrial ATP production
ATP depletion induced by inhibiting glycolysis or mitochondrial ATP production has been demonstrated to cause cancer cell death. Whether ATP depletion can enhance the efficacy and potency of anti-cancer effects of herbal compounds is so far unknown. We examined the enhancing effect of ATP depletion on anti-cancer actions of tetrandrine (TET) in human lung carcinoma A549 cells. A 24-h incubation of A549 cells with tetrandrine caused a concentration-dependent cytotoxic effect (LC50 = 66.1 μM). Co-incubation with 20 mM 2-deoxyglucose (2-DG, glycolysis inhibitor) caused only a very slight enhancement of tetrandrine cytotoxicity. By contrast, inhibiting mitochondrial ATP production with oligomycin (10 μM, ATP synthase inhibitor) and FCCP (30 μM, uncoupling agent) (thus, oligo-FCCP) on its own caused only slight cell cytotoxicity but strongly potentiated tetrandrine cytotoxicity (tetrandrine LC50 = 15.6 μM). The stronger enhancing effect of oligo-FCCP than 2-DG on TET toxicity did not result from more severe overall ATP depletion, since both treatments caused a similar ATP level suppression. Neither oligo-FCCP nor 2-DG synergized with tetrandrine in decreasing mitochondrial membrane potential. TET on its own triggered reactive oxygen species (ROS) production, and oligo-FCCP, but not 2-DG, potentiated TET in causing ROS production. Taken together, our results suggest that inhibiting ATP production from mitochondria, but not from glycolysis, appears to be a very effective means in augmenting TET-triggered ROS production and hence toxicity in A549 cells.
- 13 December 2018
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 392 (4) , 427-436
Enhancing tetrandrine cytotoxicity in human lung carcinoma A549 cells by suppressing mitochondrial ATP production
ATP depletion induced by inhibiting glycolysis or mitochondrial ATP production has been demonstrated to cause cancer cell death. Whether ATP depletion can enhance the efficacy and potency of anti-cancer effects of herbal compounds is so far unknown. We examined the enhancing effect of ATP depletion on anti-cancer actions of tetrandrine (TET) in human lung carcinoma A549 cells. A 24-h incubation of A549 cells with tetrandrine caused a concentration-dependent cytotoxic effect (LC50 = 66.1 μM). Co-incubation with 20 mM 2-deoxyglucose (2-DG, glycolysis inhibitor) caused only a very slight enhancement of tetrandrine cytotoxicity. By contrast, inhibiting mitochondrial ATP production with oligomycin (10 μM, ATP synthase inhibitor) and FCCP (30 μM, uncoupling agent) (thus, oligo-FCCP) on its own caused only slight cell cytotoxicity but strongly potentiated tetrandrine cytotoxicity (tetrandrine LC50 = 15.6 μM). The stronger enhancing effect of oligo-FCCP than 2-DG on TET toxicity did not result from more severe overall ATP depletion, since both treatments caused a similar ATP level suppression. Neither oligo-FCCP nor 2-DG synergized with tetrandrine in decreasing mitochondrial membrane potential. TET on its own triggered reactive oxygen species (ROS) production, and oligo-FCCP, but not 2-DG, potentiated TET in causing ROS production. Taken together, our results suggest that inhibiting ATP production from mitochondria, but not from glycolysis, appears to be a very effective means in augmenting TET-triggered ROS production and hence toxicity in A549 cells.
- 6 December 2010
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 112 (2) , 643-652
Phloroglucinol derivative MCPP induces cell apoptosis in human colon cancer
This study is the first to investigate the anticancer effects of the new phloroglucinol derivative (3,6‐bis(3‐chlorophenylacetyl)phloroglucinol; MCPP) in human colon cancer cells. MCPP induced cell death and antiproliferation in three human colon cancer, HCT‐116, SW480, and Caco‐2 cells, but not in primary human dermal fibroblast cells. MCPP‐induced concentration‐dependent apoptotic cell death in colon cancer cells was measured by fluorescence‐activated cell sorter (FACS) analysis. Treatment of HCT‐116 human colon cancer cells with MCPP was found to induce a number of signature endoplasmic reticulum (ER) stress markers; and up‐regulation of CCAAT/enhancer‐binding protein homologous protein (CHOP) and glucose‐regulated protein (GRP)‐78, phosphorylation of eukaryotic initiation factor‐2α (eIF‐2α), suggesting the induction of ER stress. MCPP also increased GSK3α/β(Tyr270/216) phosphorylation and reduced GSK3α/β(Ser21/9) phosphorylation time‐dependently. Transfection of cells with GRP78 or CHOP siRNA, or treatment of GSK3 inhibitor SB216163 reduced MCPP‐mediated cell apoptosis. Treatment of MCPP also increased caspase‐7, caspase‐9, and caspase‐3 activity. The inhibition of caspase activity by z‐DEVE‐FMK or z‐VAD‐FMK significantly reduced MCPP‐induced apoptosis. Furthermore, treatment of GSK3 inhibitor SB216763 also dramatically reversed MCPP‐induced GRP and CHOP up‐regulation, and pro‐caspase‐3 and pro‐caspase‐9 degradation. Taken together, the present study provides evidences to support that GRP78 and CHOP expression, and GSK3α/β activation in mediating the MCPP‐induced human colon cancer cell apoptosis. J. Cell. Biochem. 112: 643–652, 2011.
- 6 December 2010
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 112 (2) , 643-652
Phloroglucinol derivative MCPP induces cell apoptosis in human colon cancer
This study is the first to investigate the anticancer effects of the new phloroglucinol derivative (3,6‐bis(3‐chlorophenylacetyl)phloroglucinol; MCPP) in human colon cancer cells. MCPP induced cell death and antiproliferation in three human colon cancer, HCT‐116, SW480, and Caco‐2 cells, but not in primary human dermal fibroblast cells. MCPP‐induced concentration‐dependent apoptotic cell death in colon cancer cells was measured by fluorescence‐activated cell sorter (FACS) analysis. Treatment of HCT‐116 human colon cancer cells with MCPP was found to induce a number of signature endoplasmic reticulum (ER) stress markers; and up‐regulation of CCAAT/enhancer‐binding protein homologous protein (CHOP) and glucose‐regulated protein (GRP)‐78, phosphorylation of eukaryotic initiation factor‐2α (eIF‐2α), suggesting the induction of ER stress. MCPP also increased GSK3α/β(Tyr270/216) phosphorylation and reduced GSK3α/β(Ser21/9) phosphorylation time‐dependently. Transfection of cells with GRP78 or CHOP siRNA, or treatment of GSK3 inhibitor SB216163 reduced MCPP‐mediated cell apoptosis. Treatment of MCPP also increased caspase‐7, caspase‐9, and caspase‐3 activity. The inhibition of caspase activity by z‐DEVE‐FMK or z‐VAD‐FMK significantly reduced MCPP‐induced apoptosis. Furthermore, treatment of GSK3 inhibitor SB216763 also dramatically reversed MCPP‐induced GRP and CHOP up‐regulation, and pro‐caspase‐3 and pro‐caspase‐9 degradation. Taken together, the present study provides evidences to support that GRP78 and CHOP expression, and GSK3α/β activation in mediating the MCPP‐induced human colon cancer cell apoptosis. J. Cell. Biochem. 112: 643–652, 2011.
- 1 April 2010
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 110 (1) , 141-150
Bradykinin‐induced cell migration and COX‐2 production mediated by the bradykinin B1 receptor in glioma cells
Bradykinin is produced and acts at the site of injury and inflammation. Recent reports have also shown that bradykinin selectively modulates blood–tumor barrier permeability. However, the molecular mechanisms and pathologic roles underlying bradykinin‐induced glioma migration remain unclear. Glioma is the most common primary adult brain tumor, with a poor prognosis because of the ease with which tumor cells spread to other regions of the brain. In this study, we found that bradykinin increases the cell migration and expression of cyclo‐oxygenase‐2 (COX‐2) in glioma cells. Bradykinin‐mediated migration was attenuated by the selective COX‐2 inhibitor NS‐398. Moreover, increased motility of glioma cells and expression of COX‐2 were mimicked by a bradykinin B1 receptor (B1R) agonist and markedly inhibited by a B1R antagonist. Bradykinin‐mediated migration was attenuated by phosphoinositide 3‐kinase (PI‐3 kinase)/AKT inhibitors LY 294002 and wortmannin. Bradykinin stimulation also increased the phosphorylation of the p85 subunit of PI‐3 kinase and serine 473 of AKT. Treatment of bradykinin with AP‐1 inhibitors Tanshinone IIA and curcumin also reduced COX‐2 expression and glioma cell migration. Moreover, treatment of bradykinin also induced phosphorylation of c‐Jun in glioma cells. AP‐1 promoter analysis in the luciferase reporter construct showed that bradykinin increased AP‐1 transcription activity and was inhibited by LY 294002 and wortmannin. One mechanism underlying bradykinin‐directed migration is transcriptional up‐regulation of COX‐2 and activation of the B1R receptor, PI‐3 kinase, AKT, c‐Jun, and AP‐1 pathways. J. Cell. Biochem. 110: 141–150, 2010.
- 1 April 2010
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 110 (1) , 141-150
Bradykinin‐induced cell migration and COX‐2 production mediated by the bradykinin B1 receptor in glioma cells
Bradykinin is produced and acts at the site of injury and inflammation. Recent reports have also shown that bradykinin selectively modulates blood–tumor barrier permeability. However, the molecular mechanisms and pathologic roles underlying bradykinin‐induced glioma migration remain unclear. Glioma is the most common primary adult brain tumor, with a poor prognosis because of the ease with which tumor cells spread to other regions of the brain. In this study, we found that bradykinin increases the cell migration and expression of cyclo‐oxygenase‐2 (COX‐2) in glioma cells. Bradykinin‐mediated migration was attenuated by the selective COX‐2 inhibitor NS‐398. Moreover, increased motility of glioma cells and expression of COX‐2 were mimicked by a bradykinin B1 receptor (B1R) agonist and markedly inhibited by a B1R antagonist. Bradykinin‐mediated migration was attenuated by phosphoinositide 3‐kinase (PI‐3 kinase)/AKT inhibitors LY 294002 and wortmannin. Bradykinin stimulation also increased the phosphorylation of the p85 subunit of PI‐3 kinase and serine 473 of AKT. Treatment of bradykinin with AP‐1 inhibitors Tanshinone IIA and curcumin also reduced COX‐2 expression and glioma cell migration. Moreover, treatment of bradykinin also induced phosphorylation of c‐Jun in glioma cells. AP‐1 promoter analysis in the luciferase reporter construct showed that bradykinin increased AP‐1 transcription activity and was inhibited by LY 294002 and wortmannin. One mechanism underlying bradykinin‐directed migration is transcriptional up‐regulation of COX‐2 and activation of the B1R receptor, PI‐3 kinase, AKT, c‐Jun, and AP‐1 pathways. J. Cell. Biochem. 110: 141–150, 2010.
- 28 July 2009
- Published by Georg Thieme Verlag KG in Planta Medica
- Vol. 76 (01) , 34-40
Osthol is a Use-Dependent Blocker of Voltage-Gated Na+Channels in Mouse Neuroblastoma N2A Cells
Osthol, a Chinese herbal compound, has been shown to possess vasorelaxant and neuroprotective properties. Not much is known about the effects of osthol on ionic channels, activities of which are implicated in vasorelaxation and neuroprotection. In this work we report that osthol could inhibit voltage-gated Na+ currents with state-dependence in mouse neuroblastoma N2A cells (IC50 = 12.3 µM and 31.5 µM at holding potentials of − 70 mV and − 100 mV, respectively). Current blockade was equally effective in both extracellular and intracellular application of osthol. Osthol (18 µM) did not significantly affect the kinetics and voltage-dependence of Na+ channel activation, but left-shifted the steady-state inactivation curve (V1/2 = − 60.5 mV and − 78.7 mV in the absence and presence of osthol, respectively). Osthol also mildly but significantly retarded channel recovery from inactivation (recovery time constant = 19.9 ms and 35.6 ms in the absence and presence of osthol, respectively). In addition, osthol blocked Na+ currents in a frequency-dependent fashion: blockades of 17 %, 34 % and 49 % when currents were triggered at 0.33 Hz, 1 Hz and 3.33 Hz, respectively. Taken together, our results therefore suggest that osthol blocked voltage-gated Na+ channels intracellularly with state- and frequency-dependence.
- 28 July 2009
- Published by Georg Thieme Verlag KG in Planta Medica
- Vol. 76 (01) , 34-40
Osthol is a Use-Dependent Blocker of Voltage-Gated Na+Channels in Mouse Neuroblastoma N2A Cells
Osthol, a Chinese herbal compound, has been shown to possess vasorelaxant and neuroprotective properties. Not much is known about the effects of osthol on ionic channels, activities of which are implicated in vasorelaxation and neuroprotection. In this work we report that osthol could inhibit voltage-gated Na+ currents with state-dependence in mouse neuroblastoma N2A cells (IC50 = 12.3 µM and 31.5 µM at holding potentials of − 70 mV and − 100 mV, respectively). Current blockade was equally effective in both extracellular and intracellular application of osthol. Osthol (18 µM) did not significantly affect the kinetics and voltage-dependence of Na+ channel activation, but left-shifted the steady-state inactivation curve (V1/2 = − 60.5 mV and − 78.7 mV in the absence and presence of osthol, respectively). Osthol also mildly but significantly retarded channel recovery from inactivation (recovery time constant = 19.9 ms and 35.6 ms in the absence and presence of osthol, respectively). In addition, osthol blocked Na+ currents in a frequency-dependent fashion: blockades of 17 %, 34 % and 49 % when currents were triggered at 0.33 Hz, 1 Hz and 3.33 Hz, respectively. Taken together, our results therefore suggest that osthol blocked voltage-gated Na+ channels intracellularly with state- and frequency-dependence.